SG10201503350TA - Compounds for inhibiting mitotic progression - Google Patents

Compounds for inhibiting mitotic progression

Info

Publication number
SG10201503350TA
SG10201503350TA SG10201503350TA SG10201503350TA SG10201503350TA SG 10201503350T A SG10201503350T A SG 10201503350TA SG 10201503350T A SG10201503350T A SG 10201503350TA SG 10201503350T A SG10201503350T A SG 10201503350TA SG 10201503350T A SG10201503350T A SG 10201503350TA
Authority
SG
Singapore
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
inhibiting
progression
Prior art date
Application number
SG10201503350TA
Other languages
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201503350T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of SG10201503350TA publication Critical patent/SG10201503350TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG10201503350TA 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression SG10201503350TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16

Publications (1)

Publication Number Publication Date
SG10201503350TA true SG10201503350TA (en) 2015-06-29

Family

ID=39315133

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011080652A SG176443A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression
SG10201503350TA SG10201503350TA (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011080652A SG176443A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Country Status (35)

Country Link
US (6) US8026246B2 (es)
EP (4) EP2497773B1 (es)
JP (3) JP5102839B2 (es)
KR (2) KR101342014B1 (es)
CN (2) CN103483343B (es)
AR (1) AR064246A1 (es)
AT (1) ATE556076T1 (es)
AU (1) AU2007322046B2 (es)
BR (1) BRPI0718803B8 (es)
CA (1) CA2669680C (es)
CL (1) CL2007003244A1 (es)
CR (3) CR10782A (es)
CY (1) CY1112828T1 (es)
DK (2) DK2497772T3 (es)
EA (1) EA015779B1 (es)
ES (3) ES2537451T3 (es)
GE (1) GEP20125459B (es)
HK (4) HK1134672A1 (es)
HR (2) HRP20120490T1 (es)
IL (1) IL198690A0 (es)
MA (1) MA30988B1 (es)
MX (3) MX2009004670A (es)
MY (1) MY153243A (es)
NO (1) NO343338B1 (es)
NZ (3) NZ597252A (es)
PH (1) PH12012502057B1 (es)
PL (2) PL2086981T3 (es)
PT (2) PT2086981E (es)
RS (2) RS53788B1 (es)
SG (2) SG176443A1 (es)
SI (2) SI2086981T1 (es)
TW (1) TWI401255B (es)
UA (1) UA94129C2 (es)
WO (1) WO2008063525A1 (es)
ZA (1) ZA200903279B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511139B8 (pt) 2004-05-14 2021-05-25 Millennium Pharm Inc compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR074487A1 (es) * 2008-12-05 2011-01-19 Millennium Pharm Inc Tiolactamas inhibidoras de proteinquinasas plk, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de trastornos proliferativos e inflamatorios, en particular cancer.
CA2747326C (en) 2008-12-22 2017-05-16 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2013520424A (ja) * 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2011161031A1 (en) * 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
US20180263979A1 (en) * 2014-12-23 2018-09-20 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗がん剤としての複素環式の限定された三環系スルホンアミド
WO2017044567A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
MX2018011102A (es) 2016-03-15 2019-01-10 Oryzon Genomics Sa Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
IL59316A (en) 1979-02-07 1983-07-31 Sparamedica Ag Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ330973A (en) * 1996-03-08 2000-03-27 Zeneca Ltd Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
WO1999016770A1 (fr) * 1997-09-29 1999-04-08 Meiji Seika Kaisha, Ltd. Derives de triazolobenzazepine tricyclique, leur procede de production et antiallergique
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
ATE403644T1 (de) 1999-12-06 2008-08-15 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
JP2004518743A (ja) 2000-12-21 2004-06-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
CN100418955C (zh) 2001-08-09 2008-09-17 埃科特莱茵药品有限公司 新型苯并稠杂环
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
BRPI0511139B8 (pt) 2004-05-14 2021-05-25 Millennium Pharm Inc compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
PT1962830E (pt) 2005-12-23 2013-05-29 Glaxosmithkline Llc Inibidores azaindólicos de cinases aurora
JP2010500352A (ja) 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
AU2007322046A1 (en) 2008-05-29
CR20140154A (es) 2014-07-23
EP2944639A1 (en) 2015-11-18
EP2497773A1 (en) 2012-09-12
UA94129C2 (ru) 2011-04-11
CN101547924B (zh) 2013-09-25
JP5452811B2 (ja) 2014-03-26
NZ611898A (en) 2015-01-30
HRP20120490T1 (hr) 2012-07-31
US20080167292A1 (en) 2008-07-10
EP2944639B1 (en) 2017-01-04
ZA200903279B (en) 2010-07-28
US20150166545A1 (en) 2015-06-18
EP2497772B1 (en) 2014-10-29
KR101342014B1 (ko) 2013-12-19
MA30988B1 (fr) 2009-12-01
US11958855B2 (en) 2024-04-16
ATE556076T1 (de) 2012-05-15
GEP20125459B (en) 2012-03-26
CA2669680C (en) 2012-04-10
WO2008063525A1 (en) 2008-05-29
SI2086981T1 (sl) 2012-12-31
MX348568B (es) 2017-06-20
US10836766B2 (en) 2020-11-17
DK2497772T3 (en) 2015-01-19
SI2497772T1 (sl) 2015-03-31
BRPI0718803B1 (pt) 2020-11-17
KR20110113210A (ko) 2011-10-14
HK1134672A1 (en) 2010-05-07
HRP20150047T1 (en) 2015-03-13
KR20090091173A (ko) 2009-08-26
IL198690A0 (en) 2010-02-17
AU2007322046B2 (en) 2012-04-05
TW200829589A (en) 2008-07-16
RS53788B1 (en) 2015-06-30
NO343338B1 (no) 2019-02-04
EA015779B1 (ru) 2011-12-30
KR101110458B1 (ko) 2012-03-13
EP2086981A1 (en) 2009-08-12
TWI401255B (zh) 2013-07-11
US20110312942A1 (en) 2011-12-22
US20210214361A1 (en) 2021-07-15
EP2497773B1 (en) 2015-02-25
CR10782A (es) 2009-06-24
JP2012006965A (ja) 2012-01-12
HK1217699A1 (zh) 2017-01-20
RS52313B (en) 2012-12-31
US9988384B2 (en) 2018-06-05
PL2497772T3 (pl) 2015-05-29
CA2669680A1 (en) 2008-05-29
EP2497772A1 (en) 2012-09-12
CN103483343B (zh) 2016-06-01
HK1175777A1 (en) 2013-07-12
CY1112828T1 (el) 2016-02-10
AR064246A1 (es) 2009-03-25
BRPI0718803B8 (pt) 2021-05-25
NZ577042A (en) 2012-03-30
US9765076B2 (en) 2017-09-19
JP5102839B2 (ja) 2012-12-19
CR20140544A (es) 2015-01-12
US8026246B2 (en) 2011-09-27
SG176443A1 (en) 2011-12-29
ES2528793T3 (es) 2015-02-12
EP2086981B1 (en) 2012-05-02
NO20091864L (no) 2009-06-15
EA200970486A1 (ru) 2009-10-30
US20190031662A1 (en) 2019-01-31
ES2537451T3 (es) 2015-06-08
MY153243A (en) 2015-01-29
ES2384123T3 (es) 2012-06-29
US20110312943A1 (en) 2011-12-22
DK2086981T3 (da) 2012-08-06
MX343391B (es) 2016-11-04
CL2007003244A1 (es) 2008-04-04
JP2010510215A (ja) 2010-04-02
PL2086981T3 (pl) 2012-09-28
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
BRPI0718803A2 (pt) 2013-12-03
NZ597252A (en) 2013-06-28
CN101547924A (zh) 2009-09-30
PH12012502057A1 (en) 2015-09-14
JP2014055166A (ja) 2014-03-27
PH12012502057B1 (en) 2015-09-14
PT2497772E (pt) 2015-02-05
HK1175778A1 (en) 2013-07-12
CN103483343A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
HK1217699A1 (zh) 抑制有絲分裂的化合物
GB0602424D0 (en) Compounds
GB0602046D0 (en) Compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
EP2082022A4 (en) COMPOUNDS
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0602042D0 (en) Compounds
EP1973905A4 (en) COMPOUNDS
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP2016069A4 (en) BISPYRIDINIUMVERBINDUNGEN
GB0602560D0 (en) Compounds
GB0602412D0 (en) Compounds
GB0600427D0 (en) Compounds
GB0601612D0 (en) Compounds
GB0604377D0 (en) Compounds
GB0601505D0 (en) Compounds
GB0602134D0 (en) Compounds
GB0600426D0 (en) Compounds
GB0624719D0 (en) Compounds
GB0605588D0 (en) Compounds
GB0605540D0 (en) Compounds
GB0605539D0 (en) Compounds
GB0605467D0 (en) Compounds
GB0605414D0 (en) Compounds
GB0605412D0 (en) Compounds